Bastien Calmels

Summary

Affiliation: Transgene SA
Country: France

Publications

  1. ncbi Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L
    Bastien Calmels
    Molecular Immunology Laboratory, Transgene SA, Strasbourg 67082, France
    Cancer Gene Ther 12:198-205. 2005
  2. ncbi Secretomers as a new tool for the monitoring of CTL responses
    Bastien Calmels
    Transgene S A, Molecular Immunology Laboratory, Strasbourg, 67082, France
    Cancer Immunol Immunother 54:548-56. 2005
  3. ncbi Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer
    Stephane Paul
    Clinical and Experimental Immunology Laboratory, Transgene S A Strasbourg 67082, France
    Curr Gene Ther 2:91-100. 2002
  4. ncbi Therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, 11 rue de Molsheim, 67082 Strasbourg, France
    Curr Opin Mol Ther 6:40-7. 2004
  5. ncbi Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007

Detail Information

Publications5

  1. ncbi Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L
    Bastien Calmels
    Molecular Immunology Laboratory, Transgene SA, Strasbourg 67082, France
    Cancer Gene Ther 12:198-205. 2005
    ..The virus constructs were injected into growing B16 melanoma tumors. Ad-GITR-L was shown to attract infiltration with both CD4+ and CD8+ T cells. Both constructs were shown to inhibit tumor growth...
  2. ncbi Secretomers as a new tool for the monitoring of CTL responses
    Bastien Calmels
    Transgene S A, Molecular Immunology Laboratory, Strasbourg, 67082, France
    Cancer Immunol Immunother 54:548-56. 2005
    ..Infection of tumor cells with these adenovirus constructs results in the secretion of the complexes into the culture supernatant. These soluble divalent class I MHC molecules were used to detect and activate specific CTL populations...
  3. ncbi Improvement of adoptive cellular immunotherapy of human cancer using ex-vivo gene transfer
    Stephane Paul
    Clinical and Experimental Immunology Laboratory, Transgene S A Strasbourg 67082, France
    Curr Gene Ther 2:91-100. 2002
    ..In this review, we focus on the rationale and types of ex vivo gene-based immunotherapy of cancer. Finally, the use of genetically modified DC for tumor vaccination and its prospects are discussed...
  4. ncbi Therapeutic cancer vaccines
    Bruce Acres
    Transgene SA, 11 rue de Molsheim, 67082 Strasbourg, France
    Curr Opin Mol Ther 6:40-7. 2004
    ..Aggressive protocols such as those combining specific stimulation of T-cells and chemotherapy or strategies to block immune regulation are having some success...
  5. ncbi Type I IFN innate immune response to adenovirus-mediated IFN-gamma gene transfer contributes to the regression of cutaneous lymphomas
    Mirjana Urosevic
    Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
    J Clin Invest 117:2834-46. 2007
    ..Biological effects of type I IFNs seem to enhance those set in motion by the transgene, in our case IFN-gamma. This combination may prove to be of therapeutic importance in cytokine gene transfer using Ads...